Synhale Therapeutics
Cambridge, United States· Est.
Cambridge‑based biotech delivering inhaled small‑molecule therapies for pulmonary hypertension using a proprietary lung‑targeted platform.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $75M
AI Company Overview
Cambridge‑based biotech delivering inhaled small‑molecule therapies for pulmonary hypertension using a proprietary lung‑targeted platform.
Pulmonary Hypertension
Technology Platform
A proprietary inhaled formulation platform that creates respirable particles for deep lung delivery of small‑molecule drugs, enabling high local exposure with reduced systemic side effects.
Opportunities
Inhaled delivery of telaglenastat could provide a differentiated, lung‑targeted therapy for PAH, addressing unmet safety and efficacy gaps and enabling rapid market entry.
Risk Factors
Clinical efficacy and safety of inhaled telaglenastat remain unproven; regulatory pathways for repurposed inhaled agents may be complex, and competition from established oral PAH drugs is intense.
Competitive Landscape
Key competitors include Actelion (Johnson & Johnson), Gilead, and Pfizer, which focus on oral PAH agents; Synhale differentiates through its inhaled platform and metabolic‑targeted mechanism.